The United States is the global leader in biomedical innovation, discovering more new cures than … http://www.biotech-now.org/health/2017/09/new-infographic-a-response-to-a-better-deal-on-drug-pricing
FDA Commissioner Scott Gottlieb has been very public in expressing his desire to provide increased competition and greater choice to American consumers in a bid to drive down prices of prescription medicines. Recently, the agency he oversees took some unusual steps to back up those statements with action. Last week, the FDA approved the use […] http://www.xconomy.com/san-diego/2017/08/21/on-drug-pricing-fda-backs-up-its-calls-for-increased-competition/
Read recent commentaries about drug-cost issues. http://khn.org/morning-breakout/perspectives-more-transparent-pricing-system-would-help-untangle-confusion-around-high-costs/
BRUSSELS/LONDON (Reuters) – The first ever EU antitrust probe into excessive drug pricing is taking the European pharmaceuticals industry into uncharted territory, unnerving some companies and lawyers worried about the reach of market intervention.
The newly sworn-in FDA Commissioner told agency staff he hopes to speed lower cost generics to market and increase competition, particularly for complex drug products and biologics. http://www.biopharmadive.com/news/gottlieb-fda-drug-prices-generics-lower-cost/442824/
(Reuters) – French drugmaker Sanofi has pledged to peg U.S. drug price rises to below healthcare inflation in a move that limits increases for any product this year to 5.4 percent, unless there are exceptional circumstances.
Anthem dispute with Express Scripts shifts focus in battle over high drug prices https://www.ft.com/content/b6c90a12-2ebf-11e7-9555-23ef563ecf9a
Following criticism over the cost of its insulin drugs, the company gave a glimpse into its pricing decisions in an annual report. http://www.biopharmadive.com/news/Eli-lilly-pricing-report/438474/
Johnson & Johnson released its pricing data, as promised, in February and it has simply revealed that its average price increases have been below the 10% mark annually for the last five years. It follows a similar path trodden by MSD, known as Merck in North America, in the release of a brief table of price increases but levelled against the ‘Net Price Change’ that factors in rebates and reimbursements.
read more http://www.pharmafile.com/news/513441/jj-latest-pharma-firm-volunteer-pricing-data